/Investors

Tullis Health Investors — 2023 Investments

1 investments dated 2023 · listed companies and verified rows first · show all

Vedanta Biosciencesvedantabio.comin𝕏Mar 2023SEC filingmedium confidence

Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection.

BiotechHealthtechCambridge, US

Bernat Olle(Executive Officer, Director)inDaniel Couto(Executive Officer)inMark Mullikin(Executive Officer)inJeffrey Silber(Executive Officer)inChristopher Viehbacher(Director)

BoardJohn LaMattina(Director)in

Board seatCurt LaBelle· per SEC Form D · $118.5M raise · filed Aug 2024

Co-investorsAMR Action FundK2 HealthVenturesSalica InvestmentsSeventure PartnersBNP ParibasBNP Paribas Asset Management Europe+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.